You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
人福醫藥(600079.SH):琥珀酸索利那新片獲得藥品註冊批件
格隆匯 12-17 16:30

格隆匯 12 月 17日丨人福醫藥(600079.SH)公佈,公司子公司漢人福利康藥業有限公司(人福利康,公司及全資子公司合計持有其68.66%的股權,根據增資協議的遠期回購約定,公司持有其100%權益)近日收到國家藥品監督管理準簽發的琥珀酸索利那新片《藥品註冊證書》。

人福利康20189月向湖北省藥品監督管理局提交琥珀酸索利那新片的註冊申請並獲得受理,截至目前累計研發投入約為1,300萬元人民幣琥珀酸索利那新片用於膀胱過度活動症患者伴有的尿失禁和/或尿頻、尿急症狀的治療根據米內網數據統計,2019索利那新片劑在我國城市、縣級及鄉鎮三大終端公立醫院的銷售額約為6000元,城市藥店的銷售額約為2500元,主要生產廠家安斯泰來製藥(中國)有限公司川國為製藥有限公司等。

此次琥珀酸索利那新片獲批公司將根據市場需求情況,着手安排生產上市產品充實了公司產品線,其上市銷售將對公司帶來積極的影響。該產品未來的具體銷售情況可能受到行業政策、市場環境等因素影響,具有不確定性

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account